Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02807636




Registration number
NCT02807636
Ethics application status
Date submitted
17/06/2016
Date registered
21/06/2016
Date last updated
29/04/2024

Titles & IDs
Public title
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Scientific title
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Secondary ID [1] 0 0
2016-000250-35
Secondary ID [2] 0 0
WO30070
Universal Trial Number (UTN)
Trial acronym
IMvigor130
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Urothelial Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Bladder - transitional cell cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Carboplatin
Treatment: Drugs - Gemcitabine
Other interventions - Placebo
Treatment: Drugs - Cisplatin

Experimental: Atezolizumab+Gemcitabine+Carboplatin/Cisplatin - Participants will receive blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).

Placebo comparator: Placebo+Gemcitabine+Carboplatin/Cisplatin - Participants will receive blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).

Experimental: Atezolizumab Monotherapy - Eligible participants will receive open-label atezolizumab as monotherapy.


Treatment: Drugs: Atezolizumab
Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.

Treatment: Drugs: Carboplatin
Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL\*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.

Treatment: Drugs: Gemcitabine
Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.

Other interventions: Placebo
Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.

Treatment: Drugs: Cisplatin
Cisplatin will be administered at a dose of 70 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [1] 0 0
Baseline up to first documented disease progression or death, whichever occurs first (up to approximately 35 months)
Primary outcome [2] 0 0
Overall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [2] 0 0
Baseline until death due to any cause (up to approximately 73 months)
Primary outcome [3] 0 0
Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [3] 0 0
Baseline until death due to any cause (up to approximately 73 months)
Secondary outcome [1] 0 0
Objective Response Rate (ORR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [1] 0 0
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Secondary outcome [2] 0 0
Objective Response Rate (ORR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [2] 0 0
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Secondary outcome [3] 0 0
Duration of Response (DOR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [3] 0 0
From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Secondary outcome [4] 0 0
Duration of Response (DOR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [4] 0 0
From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Secondary outcome [5] 0 0
IRF-PFS
Timepoint [5] 0 0
Randomization to first documented disease progression or death from any cause (up to 35 months)
Secondary outcome [6] 0 0
OS Event Free Rate Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [6] 0 0
Year 1
Secondary outcome [7] 0 0
OS Event Free Rate in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [7] 0 0
Year 1
Secondary outcome [8] 0 0
PFS Event Free Rate
Timepoint [8] 0 0
Year 1
Secondary outcome [9] 0 0
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [9] 0 0
Up to approximately 73 months
Secondary outcome [10] 0 0
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm
Timepoint [10] 0 0
Up to approximately 73 months
Secondary outcome [11] 0 0
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [11] 0 0
Up to approximately 73 months
Secondary outcome [12] 0 0
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm
Timepoint [12] 0 0
Up to approximately 73 months
Secondary outcome [13] 0 0
Maximum Atezolizumab Serum Concentration
Timepoint [13] 0 0
Cycle 1 Day 1
Secondary outcome [14] 0 0
Minimum Atezolizumab Serum Concentration
Timepoint [14] 0 0
Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, Cycle 16 Day 1, Cycle 24 Day 1, Cycle 32 Day 1, Day 120 post dose of last blinded atezolizumab treatment, and study drug early discontinuation
Secondary outcome [15] 0 0
Percentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)
Timepoint [15] 0 0
Up to approximately 35 months
Secondary outcome [16] 0 0
Investigator-Assessed Progression-Free Survival (INV-PFS) in Participants Treated With Atezolizumab Monotherapy Arm Compared With Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Timepoint [16] 0 0
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (assessed at baseline, every 9 weeks for 54 weeks and every 12 weeks thereafter up to 35 months)
Secondary outcome [17] 0 0
Percentage of Participants With Adverse Events (AEs) Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Timepoint [17] 0 0
Baseline up to 90 months

Eligibility
Key inclusion criteria
Inclusion Criteria

* Considered to be eligible to receive platinum-based chemotherapy, in the investigator's judgment
* Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (</=) 2
* Histologically documented, locally advanced (T4b, any N; or any T, N2-3) or metastatic urothelial carcinoma (mUC) (M1, Stage IV) (also termed transitional cell carcinoma [TCC] or urothelial cell carcinoma [UCC] of the urinary tract; including renal pelvis, ureters, urinary bladder, and urethra)
* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks preferred) or at least 15 unstained slides, with an associated pathology report, for central testing and determined to be evaluable for tumor PD-L1 expression prior to study enrollment; participants who have fewer than 15 unstained slides available at baseline (but no less than [<] 10) may be eligible following discussion with the Medical Monitor
* No prior chemotherapy for inoperable locally advanced or mUC
* For participants who received prior adjuvant/neoadjuvant chemotherapy or chemo-radiation for urothelial carcinoma, a treatment-free interval more than (>) 12 months between the last treatment administration and the date of recurrence is required in order to be considered treatment naive in the metastatic setting
* Prior local intravesical chemotherapy or immunotherapy is allowed if completed at least 4 weeks prior to the initiation of study treatment
* Measurable disease, as defined by RECIST v1.1
* Adequate hematologic and end-organ function
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of carboplatin, cisplatin, or gemcitabine or for 5 months after the last dose of atezolizumab
* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment
* Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to enrolment
* Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening and prior radiographic assessments
* Participants with treated asymptomatic central nervous system (CNS) metastases are eligible, provided they meet all of the following criteria: * Evaluable or measurable disease outside the CNS * No metastases to midbrain, pons, medulla, or within 10 mm of the optic apparatus (optic nerves and chiasm) * No history of intracranial or spinal cord hemorrhage * No ongoing requirement for corticosteroid as therapy for CNS disease; anti-convulsants at a stable dose are allowed * No evidence of significant vasogenic edema * No stereotactic radiation, whole-brain radiation or neurosurgical resection within 4 weeks prior to Cycle 1, Day 1 * Radiographic demonstration of interim stability (i.e., no progression) between the completion of CNS-directed therapy and the screening radiographic study * Screening CNS radiographic study >/=4 weeks since completion of radiotherapy or surgical resection and >/=2 weeks since discontinuation of corticosteroids
* Prior treatment with CD137 agonists, anti-CTLA-4, anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
* Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to Cycle 1, Day 1 or anticipated requirement for systemic immunosuppressive medications during the study
* Leptomeningeal disease
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
* Uncontrolled tumour-related pain or hypercalcemia
* Significant cardiovascular disease including known left ventricular ejection fraction (LVEF) <40%
* Severe infections within 4 weeks before randomization or therapeutic oral or IV antibiotics within 2 weeks before randomization
* Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
* Malignancies other than urothelial carcinoma within 5 years prior to Cycle 1, Day 1
* Life expectancy of <12 weeks
* Pregnant or lactating, or intending to become pregnant during the study
* Serum albumin <25 gram per liter (g/L)
* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
* Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
* History of autoimmune disease
* Participants with prior allogeneic stem cell or solid organ transplantation
* History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan
* Positive test for human immunodeficiency virus (HIV)
* Active hepatitis B or hepatitis C
* Active tuberculosis
* Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/06/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
12/02/2024
Sample size
Target
Accrual to date
Final
1213
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Macquarie University Hospital - Macquarie Park
Recruitment hospital [2] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [3] 0 0
Lyell McEwin Hospital - Adelaide
Recruitment hospital [4] 0 0
Ashford Cancer Center Research - Kurralta Park
Recruitment hospital [5] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [6] 0 0
Cabrini Medical Centre; Oncology - Malvern
Recruitment hospital [7] 0 0
Sunshine Hospital; Oncology Research - St Albans
Recruitment postcode(s) [1] 0 0
2109 - Macquarie Park
Recruitment postcode(s) [2] 0 0
4029 - Herston
Recruitment postcode(s) [3] 0 0
5112 - Adelaide
Recruitment postcode(s) [4] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [5] 0 0
3128 - Box Hill
Recruitment postcode(s) [6] 0 0
3144 - Malvern
Recruitment postcode(s) [7] 0 0
- St Albans
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Delaware
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
South Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Tennessee
Country [16] 0 0
Belgium
State/province [16] 0 0
Charleroi
Country [17] 0 0
Belgium
State/province [17] 0 0
Gent
Country [18] 0 0
Belgium
State/province [18] 0 0
Leuven
Country [19] 0 0
Belgium
State/province [19] 0 0
Liege
Country [20] 0 0
Bosnia and Herzegovina
State/province [20] 0 0
Banja Luka
Country [21] 0 0
Bosnia and Herzegovina
State/province [21] 0 0
Sarajevo
Country [22] 0 0
Brazil
State/province [22] 0 0
MG
Country [23] 0 0
Brazil
State/province [23] 0 0
RJ
Country [24] 0 0
Brazil
State/province [24] 0 0
RS
Country [25] 0 0
Brazil
State/province [25] 0 0
SC
Country [26] 0 0
Brazil
State/province [26] 0 0
SP
Country [27] 0 0
Canada
State/province [27] 0 0
Alberta
Country [28] 0 0
Canada
State/province [28] 0 0
British Columbia
Country [29] 0 0
Canada
State/province [29] 0 0
New Brunswick
Country [30] 0 0
Canada
State/province [30] 0 0
Ontario
Country [31] 0 0
Chile
State/province [31] 0 0
Recoleta
Country [32] 0 0
Chile
State/province [32] 0 0
Santiago
Country [33] 0 0
Chile
State/province [33] 0 0
Vitacura
Country [34] 0 0
China
State/province [34] 0 0
Beijing City
Country [35] 0 0
China
State/province [35] 0 0
Beijing
Country [36] 0 0
China
State/province [36] 0 0
Chongqing
Country [37] 0 0
China
State/province [37] 0 0
Guangzhou
Country [38] 0 0
China
State/province [38] 0 0
Nanjing City
Country [39] 0 0
China
State/province [39] 0 0
Shanghai City
Country [40] 0 0
China
State/province [40] 0 0
Shanghai
Country [41] 0 0
China
State/province [41] 0 0
Tianjin
Country [42] 0 0
Czechia
State/province [42] 0 0
Brno
Country [43] 0 0
Czechia
State/province [43] 0 0
Olomouc
Country [44] 0 0
Czechia
State/province [44] 0 0
Praha 2
Country [45] 0 0
Czechia
State/province [45] 0 0
Praha 5
Country [46] 0 0
Estonia
State/province [46] 0 0
Tallinn
Country [47] 0 0
Finland
State/province [47] 0 0
Oulu
Country [48] 0 0
Finland
State/province [48] 0 0
Turku
Country [49] 0 0
Georgia
State/province [49] 0 0
Tbilisi
Country [50] 0 0
Greece
State/province [50] 0 0
Athens
Country [51] 0 0
Greece
State/province [51] 0 0
Patras
Country [52] 0 0
Hong Kong
State/province [52] 0 0
Hong Kong
Country [53] 0 0
Hong Kong
State/province [53] 0 0
N.t.
Country [54] 0 0
Israel
State/province [54] 0 0
Haifa
Country [55] 0 0
Italy
State/province [55] 0 0
Campania
Country [56] 0 0
Italy
State/province [56] 0 0
Emilia-Romagna
Country [57] 0 0
Italy
State/province [57] 0 0
Lazio
Country [58] 0 0
Italy
State/province [58] 0 0
Liguria
Country [59] 0 0
Italy
State/province [59] 0 0
Lombardia
Country [60] 0 0
Italy
State/province [60] 0 0
Piemonte
Country [61] 0 0
Italy
State/province [61] 0 0
Puglia
Country [62] 0 0
Italy
State/province [62] 0 0
Toscana
Country [63] 0 0
Italy
State/province [63] 0 0
Umbria
Country [64] 0 0
Italy
State/province [64] 0 0
Veneto
Country [65] 0 0
Japan
State/province [65] 0 0
Aichi
Country [66] 0 0
Japan
State/province [66] 0 0
Aomori
Country [67] 0 0
Japan
State/province [67] 0 0
Ehime
Country [68] 0 0
Japan
State/province [68] 0 0
Gunma
Country [69] 0 0
Japan
State/province [69] 0 0
Hokkaido
Country [70] 0 0
Japan
State/province [70] 0 0
Ibaraki
Country [71] 0 0
Japan
State/province [71] 0 0
Ishikawa
Country [72] 0 0
Japan
State/province [72] 0 0
Kumamoto
Country [73] 0 0
Japan
State/province [73] 0 0
Niigata
Country [74] 0 0
Japan
State/province [74] 0 0
Osaka
Country [75] 0 0
Japan
State/province [75] 0 0
Tokyo
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Daegu
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Incheon
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Seoul
Country [79] 0 0
Malaysia
State/province [79] 0 0
FED. Territory OF Kuala Lumpur
Country [80] 0 0
Mexico
State/province [80] 0 0
Jalisco
Country [81] 0 0
Mexico
State/province [81] 0 0
Mexico CITY (federal District)
Country [82] 0 0
Mexico
State/province [82] 0 0
Nuevo LEON
Country [83] 0 0
Mexico
State/province [83] 0 0
Queretaro
Country [84] 0 0
Netherlands
State/province [84] 0 0
Den-Haag
Country [85] 0 0
Netherlands
State/province [85] 0 0
Groningen
Country [86] 0 0
Netherlands
State/province [86] 0 0
Sittard-Geleen
Country [87] 0 0
Netherlands
State/province [87] 0 0
Zwolle
Country [88] 0 0
Poland
State/province [88] 0 0
Bialystok
Country [89] 0 0
Poland
State/province [89] 0 0
Konin
Country [90] 0 0
Poland
State/province [90] 0 0
Kraków
Country [91] 0 0
Poland
State/province [91] 0 0
Lodz
Country [92] 0 0
Poland
State/province [92] 0 0
Poznan
Country [93] 0 0
Poland
State/province [93] 0 0
Tomaszów Mazowiecki
Country [94] 0 0
Poland
State/province [94] 0 0
Warszawa
Country [95] 0 0
Poland
State/province [95] 0 0
Wroclaw
Country [96] 0 0
Portugal
State/province [96] 0 0
Lisboa
Country [97] 0 0
Portugal
State/province [97] 0 0
Porto
Country [98] 0 0
Romania
State/province [98] 0 0
Baia Mare
Country [99] 0 0
Romania
State/province [99] 0 0
Bucharest
Country [100] 0 0
Romania
State/province [100] 0 0
Craiova
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Altaj
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Baskortostan
Country [103] 0 0
Russian Federation
State/province [103] 0 0
Krasnodar
Country [104] 0 0
Russian Federation
State/province [104] 0 0
Moskovskaja Oblast
Country [105] 0 0
Russian Federation
State/province [105] 0 0
Niznij Novgorod
Country [106] 0 0
Russian Federation
State/province [106] 0 0
Sankt Petersburg
Country [107] 0 0
Russian Federation
State/province [107] 0 0
Sverdlovsk
Country [108] 0 0
Russian Federation
State/province [108] 0 0
Ivanovo
Country [109] 0 0
Serbia
State/province [109] 0 0
Belgrade
Country [110] 0 0
Serbia
State/province [110] 0 0
Nis
Country [111] 0 0
Serbia
State/province [111] 0 0
Sremska Kamenica
Country [112] 0 0
Singapore
State/province [112] 0 0
Singapore
Country [113] 0 0
Slovenia
State/province [113] 0 0
Ljubljana
Country [114] 0 0
South Africa
State/province [114] 0 0
George
Country [115] 0 0
South Africa
State/province [115] 0 0
Port Elizabeth
Country [116] 0 0
South Africa
State/province [116] 0 0
Pretoria
Country [117] 0 0
South Africa
State/province [117] 0 0
Sandton
Country [118] 0 0
Spain
State/province [118] 0 0
Alicante
Country [119] 0 0
Spain
State/province [119] 0 0
Barcelona
Country [120] 0 0
Spain
State/province [120] 0 0
Cantabria
Country [121] 0 0
Spain
State/province [121] 0 0
Castellon
Country [122] 0 0
Spain
State/province [122] 0 0
Cordoba
Country [123] 0 0
Spain
State/province [123] 0 0
Islas Baleares
Country [124] 0 0
Spain
State/province [124] 0 0
Navarra
Country [125] 0 0
Spain
State/province [125] 0 0
Pontevedra
Country [126] 0 0
Spain
State/province [126] 0 0
Vizcaya
Country [127] 0 0
Spain
State/province [127] 0 0
Albacete
Country [128] 0 0
Spain
State/province [128] 0 0
Burgos
Country [129] 0 0
Spain
State/province [129] 0 0
Caceres
Country [130] 0 0
Spain
State/province [130] 0 0
Granada
Country [131] 0 0
Spain
State/province [131] 0 0
Huelva
Country [132] 0 0
Spain
State/province [132] 0 0
Jaen
Country [133] 0 0
Spain
State/province [133] 0 0
Leon
Country [134] 0 0
Spain
State/province [134] 0 0
Lugo
Country [135] 0 0
Spain
State/province [135] 0 0
Madrid
Country [136] 0 0
Spain
State/province [136] 0 0
Sevilla
Country [137] 0 0
Spain
State/province [137] 0 0
Toledo
Country [138] 0 0
Spain
State/province [138] 0 0
Valencia
Country [139] 0 0
Spain
State/province [139] 0 0
Zaragoza
Country [140] 0 0
Taiwan
State/province [140] 0 0
Kaohisung
Country [141] 0 0
Taiwan
State/province [141] 0 0
Taichung
Country [142] 0 0
Taiwan
State/province [142] 0 0
Tainan
Country [143] 0 0
Taiwan
State/province [143] 0 0
Taipei
Country [144] 0 0
Taiwan
State/province [144] 0 0
Taoyuan
Country [145] 0 0
Thailand
State/province [145] 0 0
Bangkok
Country [146] 0 0
Thailand
State/province [146] 0 0
ChiangMai
Country [147] 0 0
Turkey
State/province [147] 0 0
Adana
Country [148] 0 0
Turkey
State/province [148] 0 0
Ankara
Country [149] 0 0
Turkey
State/province [149] 0 0
Edirne
Country [150] 0 0
Turkey
State/province [150] 0 0
Istanbul
Country [151] 0 0
Turkey
State/province [151] 0 0
Kadiköy
Country [152] 0 0
Turkey
State/province [152] 0 0
Kar??yaka
Country [153] 0 0
Turkey
State/province [153] 0 0
Samsun
Country [154] 0 0
Turkey
State/province [154] 0 0
Sihhiye/Ankara
Country [155] 0 0
Ukraine
State/province [155] 0 0
Kharkiv Governorate
Country [156] 0 0
Ukraine
State/province [156] 0 0
Dnipropetrovsk
Country [157] 0 0
Ukraine
State/province [157] 0 0
Zaporizhzhia
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Glasgow
Country [159] 0 0
United Kingdom
State/province [159] 0 0
London
Country [160] 0 0
United Kingdom
State/province [160] 0 0
Manchester
Country [161] 0 0
United Kingdom
State/province [161] 0 0
York

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.
Trial website
https://clinicaltrials.gov/study/NCT02807636
Trial related presentations / publications
Galsky MD, Arija JAA, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, Ozguroglu M, Kalebasty AR, Park SH, Alekseev B, Schutz FA, Li JR, Ye D, Vogelzang NJ, Bernhard S, Tayama D, Mariathasan S, Mecke A, Thastrom A, Grande E; IMvigor130 Study Group. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020 May 16;395(10236):1547-1557. doi: 10.1016/S0140-6736(20)30230-0.
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Duran I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thastrom A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Erratum In: Lancet. 2017 Aug 26;390(10097):848. doi: 10.1016/S0140-6736(17)32213-4.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02807636